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Abstract
Hepatitis C virus (HCV) is one of the main causes of liver
disease worldwide. Liver steatosis is a common finding in
many hepatic and extrahepatic disorders, the most common
beingmetabolic syndrome (MS). Over time, it has been shown
that the frequent coexistence of these two conditions is not
coincidental, since many epidemiological, clinical, and exper-
imental studies have indicated HCV to be strongly associated
with liver steatosis and numerous metabolic derangements.
Here, we present an overview of publications that provide
clinical evidence of the metabolic effects of HCV and summa-
rize the available data on the pathogenetic mechanisms
of this association. It has been shown that HCV infection
can induce insulin resistance (IR) in the liver and peripheral
tissues through multiple mechanisms. Substantial research
has suggested that HCV interferes with insulin signaling both
directly and indirectly, inducing the production of several
proinflammatory cytokines. HCV replication, assembly, and
release from hepatocytes require close interactions with lipid
droplets and host lipoproteins. This modulation of lipid me-
tabolism in host cells can induce hepatic steatosis, which is
more pronounced in patients with HCV genotype 3. The risk
of steatosis depends on several viral factors (including
genotype, viral load, and gene mutations) and host features
(visceral obesity, type 2 diabetes mellitus, genetic predispo-
sition, medication use, and alcohol consumption). HCV-
related IR and steatosis have been shown to have a remarkable
clinical impact on the prognosis of HCV infection and quality
of life, due to their association with resistance to antiviral
therapy, progression of hepatic fibrosis, and development of
hepatocellular carcinoma. Finally, HCV-induced IR, oxidative
stress, and changes in lipid and ironmetabolism lead to glucose
intolerance, arterial hypertension, hyperuricemia, and athero-
sclerosis, resulting in increased cardiovascular mortality.
© 2016 The Second Affiliated Hospital of Chongqing Medical
University. Published by XIA & HE Publishing Inc. All rights re-
served.
Introduction
Hepatitis C virus (HCV) is a single-stranded RNA virus belong-
ing to the Flaviviridae family. Approximately 64–103 million
people are infected with HCV worldwide, making HCV one of
themajor causes of chronic liver disease.1 Acute infectionmay
resolve spontaneously in 15%–45% of cases, but the remain-
ing 55%–85% of infected individuals (75%–85% according to
serologic surveys) fail to clear the virus and become chroni-
cally infected.1,2 In a significant number of patients, chronic
hepatitis C (CHC) will progress to cirrhosis and hepatocellular
carcinoma (HCC), which represent the end-stage HCV-related
liver disease, and are among the leading causes for liver trans-
plantation in the Western world.2 Approximately 350,000 to
500,000 people die each year from hepatitis C-related liver
diseases around the world.1
The primary host cells for HCV are hepatocytes, although
replication may also occur in other cell types, such as periph-
eral blood mononuclear cells and B and T lymphocytes.3,4 HCV
interferes with the hepatic lipid metabolism throughout its life
cycle. Viral entry into hepatocytes occurs following its binding
to low-density lipoprotein receptors.5,6 Once internalized, HCV
interferes with the host lipid metabolism for its replication and
assembly, which consequently leads to hepatic steatosis.
Finally, the virus is released from the hepatocyte via the very
low-density lipoprotein secretion pathway.7
Hepatic steatosis is a condition in which there is excessive
accumulation of triglycerides within the hepatocytes. The
most common causes are alcohol consumption (alcoholic
fatty liver disease) and insulin resistance (IR) within the
metabolic syndrome (MS) (non-alcoholic fatty liver disease -
NAFLD), but other causes, including malnutrition, total paren-
teral nutrition, severe weight loss, gastrointestinal bypasses,
some inherited metabolic conditions (e.g., abetalipopro-
teinemia), glycogen storage diseases, lipodystrophy, alpha
1-antitrypsin deficiency, pregnancy, drugs and toxins, as well
as human immunodeficiency virus (HIV) and chronic HCV
infection, are also responsible for a number of cases.
NAFLD is one of the most common causes of chronic liver
disease in the Western world. It represents a spectrum of
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conditions ranging from simple steatosis to nonalcoholic
steatohepatitis (NASH), where steatosis is associated with
hepatic inflammation and various degrees of fibrosis and
cirrhosis, which develops as a consequence of long-standing
NASH.8 NAFLD is estimated to affect around 25%–30% of the
general population, while NASH is reported in 2%–3% of the
population.9
Strong epidemiological, biochemical, and therapeutic evi-
dence implicate IR as the primary pathophysiological derange-
ment and the key mechanism leading to hepatic steatosis.
Indeed, NAFLD is regarded as a hepatic manifestation of
the MS.
MS represents a combination of well-known and estab-
lished cardiovascular disease related risk factors. Multiple
definitions of MS exist with several revisions; and although
criteria differ, the essential components of MS include insulin
resistance/hyperglycemia, dyslipidemia, hypertension, and
visceral obesity.10–14 These factors have a tendency of clus-
tering together, and individuals with MS have a 2-fold inc-
rease in cardiovascular outcomes and a 1.5-fold increase in
all-cause mortality.15
Hepatic steatosis in CHC infection results from the combi-
nation of several host and viral factors that directly interfere
with lipid metabolism within the hepatocytes or cause differ-
ent metabolic derangements through IR. Host factors include
the before mentioned components of MS, such as obesity
and type 2 diabetes mellitus (T2DM); but also include
alcohol consumption, medication use, and genetic predispo-
sition (e.g., interleukin (IL) 28B polymorphism).16,17 Viral
factors include genotype (genotype 3 causing the most pro-
nounced steatosis), HCV RNA load, and gene mutations.16–18
HCV and insulin resistance
Glucose metabolism impairment, development of IR, and
T2DM can often be found accompanying CHC and is com-
monly measured using the homeostatic model assessment
(HOMA) index. Euglycemic insulin clamp studies have shown
that IR in CHC has both a hepatic and a peripheral component
and induces an array of host metabolic changes.19,20 Besides
promoting steatosis and fibrosis progression, the presence of
IR has been shown to impair treatement response and, vice-
versa, regress following successful treatment outcome.
Several studies have assessed IR in hepatitis C patients
before and after interferon therapy. Petit et al. report that IR
in nondiabetic HCV-infected patients was related to grading of
liver fibrosis and may occur early in the course of HCV infec-
tion.21 In a study including 260 HCV-infected subjects, Hui
et al. found that HCV may induce IR irrespective of the
severity of liver disease and that genotype 3 had a signifi-
cantly lower HOMA-IR than other genotypes.22 On the other
hand, another study found that median HOMA-IR was signifi-
cantly higher in patients with genotype 1 related steatosis
than in those with genotype 3 related steatosis.23 Irrespec-
tive of the genotype, higher HCV RNA levels were associated
with the presence of IR and, accordingly, the severity of
hepatic steatosis,24,25 where treatment and clearance of
HCV improved IR.26–28 Regarding the impact of HCV infection
on the development of T2DM, a meta-analysis of 34 studies
found a positive correlation between HCV infection and
increased risk of T2DM in comparison to the general popula-
tion in both retrospective and prospective studies.29 Studies
investigating the association between HCV and IR, and their
key findings, are summarized in Table 1.
HCV and hepatic steatosis
Hepatic steatosis was reported to be a histologic feature of
non-A, non-B (NANB) hepatitis several years before hepatitis
C testing was available, and it was considered common
enough to be used as a diagnostic aid in the absence of
serological diagnostic tests for hepatitis C.55,56 Steatosis
occurs in 40%–86% of patients with chronic hepatitis C,
and its frequency varies with genotype.16–18 As already men-
tioned, steatosis is more common in genotype 3 infection,
where it occurs in 73% of patients, while the prevalence of
steatosis in patients infected with other genotypes is around
50%.16–18 Infection with HCV genotype 3 is also associated
with higher steatosis scores than in other genotypes, even in
the absence of the metabolic risk factors associated with
NAFLD, and there is a significant correlation between the
degree of steatosis and the HCV RNA viral load.57,58 It has
also been demonstrated in patients infected with HCV geno-
type 3 that steatosis can improve and even disappear follow-
ing successful treatment with interferon (IFN) and ribavirin
(RBV).58 Recent studies investigating the role of a single-
nucleotide polymorphism near the IL28B gene found that
steatosis is less prevalent in carriers of the IL28B CC geno-
type, who also show less pronounced disturbances of lipid
metabolism and a favorable response to IFN therapy.59
Studies investigating the association between HCV and
hepatic steatosis, and their key findings, are summarized in
Table 2.
Pathogenesis of insulin resistance and steatosis in HCV
infection
The pathogenesis of IR and steatosis in HCV infection is a very
intriguing problem, and extensive research of this topic has
been undertaken. Different pathogenetic mechanisms have
been proposed to explain the development of IR in HCV
infected patients.90–95
In vitro and animal studies have greatly contributed to
our understanding of both lipid and glucose metabolism
alterations induced by HCV. Glucose transporter 2 (GLUT2),
responsible for transporting glucose to hepatocytes, is down-
regulated by the HCV core protein, while the overproduction
of tumor necrosis factor alpha (TNF-a), induced by HCV
infection, inhibits insulin receptor substrate (IRS) and phos-
phatidylinositol 3 kinase (PI3K) via suppressor of cytokine
sign-aling (SOCS)-3. These impairments of intracellular
insulin signaling could block GLUT-4 activation, reducing the
uptake of glucose by cells.96–98
Other cytokines besides TNF-a, such as IL-6 as well as a
number of adipokines, have been shown to play a part in IR
and steatosis pathogenesis of NAFLD, and evidence on their
influence in HCV-induced metabolic changes continue to
grow.99,100 HCV infection has also been suggested to cause
mitochondrial dysfunction and endoplasmic reticulum impair-
ment, while the genotype 3 HCV core protein has been shown
to downregulate peroxisome proliferator activating receptor
(PPARg) and upregulate SOCS-7, leading to further impair-
ment of insulin signaling.101–103
As for human studies, in a landmark study using liver biopsy
specimens (LBS) obtained from nonobese, nondiabetic HCV-
infected patients, HCV inhibited the insulin-stimulated tyrosine
phosphorylation of hepatic insulin receptor substrate-1
(IRS-1), resulting in inhibition of the PI3K-Akt pathway, a
key transducer of the insulin metabolic signal.104,105 HCV
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Table 1. The association between hepatitis C virus (HCV) and insulin resistance
Methods/Study population Findings and conclusions Author
15 CHC patients assessed before and after
IFNa therapy
Glucose tolerance improved after IFNa
treatment
Tanaka et al.,30 1997
13 nondiabetic CHC patients before and
after IFNa therapy
HCV-induced liver injury related to
deterioration of insulin sensitivity and
impaired glucose homeostasis
Konrad et al.,31 2000
103 nondiabetic CHC patients IR related to grading of liver fibrosis and
occurred at an early stage of HCV infection
Petit et al.,21 2001
160 patients with CHC Circulating insulin levels increased with
fibrosis in overweight patients with CHC
Hickman et al.,32 2003
260 CHC patients HCV may induce IR irrespective of the
severity of liver disease. Genotype 3
associated with lower HOMA-IR
Hui et al.,22 2003
141 nondiabetic CHC patients IR was significantly higher in patients
with genotype 1 related steatosis than in
genotype 3
Fartoux et al.,23 2005
159 patients with CHC genotype 1 (113) and
non-1 genotype (46) treated with IFN/RBV
SVR independently related to genotype, IR,
and fibrosis
Romero-Gómez et al.,33 2005
90 patients with CHC and 90 with NAFLD Basal and postload IR were lower in CHC
patients than in NAFLD
Svegliati-Baroni et al.,34 2007
17 CHC patients not receiving
pharmacological treatment
70% overweight or obese, 77% presented
with IR
Vázquez-Vandyck et al.,35 2007
89 CHC patients receiving IFNa or IFNa/RBV HCV clearance improved IR, b-cell function,
and hepatic IRS1&2 expression
Kawaguchi et al.,26 2007
232 CHC and 56 HCV eradicated patients CHC patients had higher prevalence of
T2DM and IR
Imazeki et al.,36 2008
162 CHC patients assessed before treatment Higher HCV RNA levels associated with the
presence of IR and hepatic steatosis
Hsu et al.,24 2008
346 untreated, nondiabetic CHC patients
with genotype 1 or 3
HOMA-IR rather than steatosis was
independently associated with fibrosis
regardless of genotype
Cua et al.,37 2008
201 CHC patients with genotype 1 IR and overt diabetes were related to
advanced fibrosis, regardless of steatosis
Petta et al.,38 2008
82 CHC patients treated with either IFN/RBV
(59) or pegylated-IFN/RBV (23)
Patients with lower HOMA-IR were more
likely to achieve SVR
Poustchi et al.,39 2008
34 postliver transplant patients evaluated
(14 HCV positive and 20 HCV negative)
Higher IR in the HCV positive group.
Higher HCV RNA levels were associated
with higher HOMA-IR
Delgado-Borrego et al.,40 2008
500 CHC patients IR was present in 32.4% of nondiabetic CHC,
associated with genotypes 1 and 4 as well as
high HCV RNA levels. Fibrosis was associated
with IR independent from steatosis
Moucari et al.,25 2008
Meta-analysis including 34 studies of HCV
infected patients
T2DM risk was higher in HCV-infected in both
retrospective and prospective studies
White et al.,29 2008
275 nondiabetic treatment-naïve CHC
patients
IR was increased in 37% of patients,
contributing to fibrosis progression, and was
more prevalent in obese patients with
steatosis. No connections with genotype or
viremia.
Tsochatzis et al.,41 2009
28 CHC patients treated with pegylated-
IFNa2a/RBV
Disappearance of HCV RNA at 6 months after
treatment independently reduced IR
Kim et al.,27 2009
38 CHC patients and healthy controls IR was positively correlated with HCV
infection and liver fibrosis
Mohamed et al.,42 2009
(continued )
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core protein was thus shown to impair hepatocyte insulin
signaling by increasing cytokine production, predominantly
TNF-a, activating SOCS, and inhibiting IRS through several
mechanisms.
All these mechanisms are probably responsible for hepatic
IR. However, there is also evidence of significant peripheral
IR in HCV infection. Milner et al., using a hyperinsulinemic-
euglycemic clamp, found no difference in hepatic glucose
production and nonesterified free fatty acids suppresion with
insulin between CHC patients and controls, suggesting IR is
predominantly in muscles.20 Vanii et al. approximated the
contribution of peripheral IR in CHC to reach 80%.19 The
role of liver-derived circulating factors (hepatokines), as pos-
sible mediators of the liver-muscle crosstalk, has yet to be
fully elucidated.106
The development of steatosis is also probably a result of
several mechanisms. Both HCV induced and host related IR as
well as metabolic factors are important for its development;
it is also, however, a consequence of derangements of lipid
metabolism caused directly by HCV.16
The influence of HCV on cholesterol and lipogenesis path-
ways of hepatocytes is a crucial part of its life cycle. HCV core
Table 1. (continued )
Methods/Study population Findings and conclusions Author
14 patients with CHC (without MS) and
7 healthy controls
HCV infection was associated with peripheral
and hepatic IR
Vanni et al.,19 2009
170 HCV mono-infected nad 170 HIV/HCV
co-infected patients
IR was associated with liver fibrosis and
steatosis in HCV mono-infected.
Halfon et al.,43 2009
96 CHC non-genotype 3 patients with
advanced fibrosis treated with pegylated-
IFN/RBV
HCV suppression was correlated with
improvement in IR independent from
potential confounders
Delgado-Borrego et al.,28 2010
188 patients in with different stages of HCV
infection
IR, regardless of presence of T2DM, was
significantly associated with HCC in patients
with CHC
Hung et al.,44 2010
40 CHC genotype 1 patients enrolled in a
study of danoprevir
HOMA-IR improvement was correlated with a
decrease in viral load
Moucari et al.,45 2010
92 untreated consecutive male CHC patients IR was detected in 63 (69%) patients. IR was
associated with steatosis.
Ahmed et al.,46 2011
1,038 treatment-naive CHC patients
enrolled in albinterferon alpha-2b vs.
pegylated-IFNa2a study
SVR was independently associated with
significant reduction in HOMA-IR in patients
with genotype 1, not in genotypes 2 or 3
Thompson et al.,47 2012
50 noncirrhotic, nondiabetic CHC patients
(27 untreated, 23 treated with pegylated-
IFN/RBV)
IR was not strongly associated with SVR. HCV
therapy may improve IR regardless of
virologic response
Brandman et al.,48 2012
140 CHC patients treated with pegylated-
IFNa2a/RBV for 48 weeks
SVR was significantly lower in the IR-HCV
group compared with the non-IR-HCV.
Plasma insulin levels and HOMA-IR were
decreased significantly in patients with SVR
Ziada et al.,49 2012
431 CHC patients receiving pegylated-
IFNa2a/RBV or pegylated-IFNa2b/RBV
SVR prevented development of de novo IR in
nondiabetic patients with CHC
Aghemo et al.,50 2012
155 anti-HCV positive patients without
T2DM, hypercortisolism, thyroid disease,
hyperlipidemia or infective diseases
79 (51%) patients had elevated HOMA-IR Kiran et al.,51 2013
102 nondiabetic and non-cirrhotic CHC
patients (69% genotype 1)
25% of subjects had IR. HCV viral load and
genotype did not influence IR
Mukhtar et al.,52 2013
30 CHC patients and 8 healthy controls
underwent a fasting test
9 CHC patients had elevated HOMA-IR. Total
ketone body change rate was lower in CHC
patients. Mitochondrial b-oxidation
impairment due to HCV infection suggested
Sato et al.,53 2013
44 treatment naive patients with genotype
1 or 3
IR was found in 27 (61%) and significant
steatosis in 37 (84%) patients. No difference
in IR between genotypes. IR associated with
higher levels of liver fibrosis and steatosis.
Péres et al.,54 2013
CHC, chronic hepatitis C; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; HOMA, homeostatic model assessment; HIV, human immunodeficiency virus; IFNa,
interferon-a; IRS, insulin receptor substrate; IR, insulin resistance; MS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; SVR, sustained viral response; T2DM,
type 2 diabetes mellitus.
Journal of Clinical and Translational Hepatology 2016 vol. 4 | 66–75 69
Kralj D. et al: HCV, IR and Steatosis
Table 2. The association between HCV and hepatic steatosis
Methods/Study population Findings and conclusions Authors
240 LBS from patients with acute hepatitis A
(86 patients), B (78 patients), and NANB
(76 patients)
Steatosis was found in 26% of NANB hepatitis
patients compared to 10% of hepatitis A and 6%
of B patients
Kryger et al.,60 1982
181 LBS from 94 patients with chronic NANB
hepatitis
Microvesicular steatosis was found in 59% of
patients and was considered a typical sign of the
chronic NANB
Wiese et al.,56 1985
LBS from 39 patients with chronic NANB
hepatitis during evaluation and follow-up
Fatty metamorphosis noted in 20 (51%) patients Di Bisceglie et al.,61 1991
LBS from 50 patients with CHC and 21 patients
with autoimmune chronic hepatitis
Steatosis was more common in patients with
CHC (72% vs. 19%)
Bach et al.,62 1992
54 LBS from 45 patients with CHC Fatty change present in 29/54 (54%) specimens Scheuer et al.,63 1992
LBS from 358 anti-HCV positive patients Steatosis was a prominent feature in patients
with chronic HCV infection
Giusti et al.,64 1993
Comparison of 317 HCV and 299 HBV LBS Large-droplet fat droplets more likely to be seen
in HCV
Lefkowitch et al.,65 1993
LBS from 55 asymptomatic anti-HCV positive
blood donors
Steatosis present in 47% McMahon et al.,66 1994
LBS from 148 patients with chronic hepatitis of
which 121 (81.8%) were HCV-positive
Steatosis found in 60% of HCV-positive and in
52% of HCV-negative patients. No significant
association between steatosis and HCV was
found
Fiore et al.,67 1996
LBS from 90 patients with CHC compared
according to genotype
Steatosis was more prevalent in patients
with HCV genotype 3a compared to genotypes
1a or 1b
Mihm et al.,68 1997
LBS from 60 CHC patients compared to 18
patients with chronic hepatitis B and 41 with
nonalcoholic steatohepatitis
Fat deposition occurred more often in patients
with CHC than in chronic hepatitis B (52%
versus 22%)
Czaja et al.,69 1998
LBS from 43 CHC patients Steatosis was observed in 21 (48.8%) patients Fujie et al.,70 1999
LBS from 148 CHC untreated patients 91 patients (61%) had steatosis of various grade Hourigan et al.,71 1999
LBS from 101 HCV-infected patients without
other risk factors for a fatty liver
Steatosis was found in 41 (40.6%) patients. HCV
genotype 3 was associated with higher steatosis
scores
Rubbia-Brandt et al.,57
2000
LBS from 170 CHC patients Steatosis was found in 90 (52.9%) patients Ong et al.,72 2001
LBS from 180 consecutive CHC patients and 41
additional subjects with a known duration of
infection
86 (48%) patients showed steatosis. Genotype
3a was associated with a higher prevalence
Adinolfi et al.,73 2001
LBS from 100 male patients with untreated
noncirrhotic CHC
Hypobetalipoproteinemia and genotype 3 were
associated with steatosis in CHC patients
Serfaty et al.,74 2001
Pre- and post-treatment LBS from 28 HCV
genotype 1 and 34 genotype 3 patients
Steatosis was initially present in 16 (57%)
patients with HCV genotype 1 and 21 (62%)
patients with genotype 3. Achieving SVR greatly
reduced steatosis in genotype 3 patients, but not
in genotype 1
Kumar et al.,75 2002
LBS from 97 CHC patients Steatosis was present in 171 patients (57.6%)
with BMI and genotype 3a as independent
predictors
Monto A et al.,76 2002
Paired LBS from 98 CHC patients prior to
antiviral treatment
41 (42%) showed signs of steatosis. Prevalence
and grade of steatosis were strongly associated
with HCV genotype 3
Westin et al.,77 2002
LBS from 124 CHC patients 90 (73%) specimens showed signs of steatosis.
Genotype 3 was associated with increased
steatosis grade
Hui et al.,78 2002
(continued )
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Table 2. (continued )
Methods/Study population Findings and conclusions Authors
Paired LBS (mean interval time of 48 months)
were evaluated in 96 patients with CHC
Steatosis was initially found in 51 (54%) of
patients. Worsening of steatosis was observed in
34% of patients, stability in 50%, and
improvement in 16%
Castéra et al.,79 2003
LBS from 1,428 treatment naïve patients were
assessed at baseline and 24 weeks after
treatment with peginterferon or interferon
a-2b and ribavirin
At baseline, steatosis was present in 935 of
1428 patients (65%), including 175 of 210
patients (83%) with genotype 3 versus 760 of
1218 (62%) with other genotypes. Steatosis
was associated with genotype 3, fibrosis and
lower SVR
Poynard et al.,56 2003
LBS from 290 CHC patients 135 patients (46.6%) had steatosis, and it was
associated with HCV genotype 3, higher grade of
necroinflammation, and higher BMI
Asselah et al.,80 2003
LBS from 755 CHC patients Steatosis was found in 315 (42%) and fibrosis in
605 patients. Steatosis was independently
associated with fibrosis, genotype 3, BMI,
ongoing alcohol abuse and age
Rubbia-Brandt et al.,81
2004
LBS from 574 CHC patients Steatosis was present in 277 (48%) of patients.
Severity of steatosis was associated with BMI,
HCV genotype 3, age, and duration of infection
Patton et al.,82 2004
Paired LBS (median interval of 61 months)
from 135 untreated CHC patients with a
METAVIR score of A1F1 or lower on first liver
biopsy
Steatosis was the only independent factor
predictive of progression of fibrosis regardless of
genotype
Fartoux et al.,83 2005
LBS from two cohorts with a total of 325
genotype 1 HCV infected patients were
analyzed for the presence and severity of
steatosis in relation to the rs12979860
polymorphism at the IL28B locus
Steatosis was found in 67.4% (89/132) of IL28B
non-CC patients compared to 39.6% (19/48) of
CC patients
Tilmann et al.,59 2011
LBS from 92 untreated males with CHC Steatosis was found in 54% of patients and was
associated with IR
Ahmed et al.,46 2011
LBS from 152 liver transplant recipients with
HCV followed up for a median of 2.09 years
Steatosis was frequent (29.6%) in the early
post-transplant period and its presence within
the first year carried a higher risk of fibrosis
progression
Brandman et al.,84 2011
LBS from 148 CHC patients Steatosis was found in 40 patients (27%). No
correlation with fibrosis or response to combined
antiviral therapy was found
Rafi et al.,85 2011
LBS from 50 HCV positive patients 28 (56%) patients had steatosis, and it was
associated with age and triglycerides levels
Ouakaa-Kchaou et al.,86
2011
LBS from 50 patients with HCV genotype 2 and
256 with HCV genotype 3
Steatosis was present in 72% of patients.
Advanced liver fibrosis and hepatic steatosis
were more common in HCV genotype 3
Melo et al.,87 2014
LBS from 330 patients with chronic hepatitis
(66 HBV, 198 HCV, and 66 HBV-HCV co-
infected)
Steatosis prevalence was comparable between
the HBV-HCV co-infected and HCV groups
(47.0% vs 49.5%, respectively). HBV group
showed lowest steatosis rates (33.3%)
Zampino R et al.,88 2014
110 HBV infected, 111 HCV infected and 136
NAFLD patients were evaluated using steatosis
biomarkers (SteatoTest > 0.38 as a surrogate
for steatosis > 5%)
Prevalence of steatosis was 21% in chronic
hepatitis B, 43% in CHC and 82% in NAFLD
patients
Pais et al.,89 2015
BMI, body mass index; CHC, chronic hepatitis C; HBV, hepatitis B virus; HCV, hepatitis C virus; LBS, liver biopsy specimens; NANB, non-A, non-B; NAFLD, non-alcoholic fatty
liver disease; SVR, sustained viral response; IR, insulin resistance.
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protein plays a major role in the replication process by inducing
accumulation of lipid droplets as well as lipogenic gene and
protein activity, consequently manifesting as hepatic steato-
sis.107 Main mechanisms of HCV-induced hepatic steatosis
include promotion of lipogenesis, impairment of mitochondrial
lipid oxidation, and decreased microsomal triglyceride transfer
protein (MTTP) activity.108,109
The activity of the HCV core protein decreases the expres-
sion and activity of the nuclear PPAR-a/g, which, besides
being strongly involved in lipid and lipoprotein metabolism,
seem to have a protective effect against hepatic inflammation
and fibrosis. The analysis of PPAR-a expression in LBS of 86
untreated patients with HCV and controls found it to be deeply
impaired.110 The HCV core protein also induces hepatic fat
accumulation by activating the sterol regulatory element-
binding protein-1c (SREBP-1c), a transcription factor regulat-
ing lipogenesis.111 A study in transgenic mice expressing the
full HCV protein repertoire showed maturational activation
and nuclear translocation of SREBP-1c, resulting in increased
lipogenic enzyme transcription.112 The factors involved in
pathogenesis of metabolic changes in HCV infection as well
as clinical outcomes are shown in Fig. 1.
Clinical consequences of hepatitis C associated
steatosis and IR
The presence of both steatosis and IR in CHC may affect
fibrosis and therapy outcomes as well as promote athero-
sclerosis and hepatic malignancy.
Liver fibrosis severity and progression are associated with
hepatic steatosis and can be used as a clinically relevant
parameter regarding starting and prioritizing treatment in
CHC patients.77,82,113,114
IR, independent of other factors, is significantly associated
with HCC development in patients with CHC.44
Of furtherclinical relevance,primarily inareaswhere IFN-free
regimens with direct-acting antivirals are not yet the standard
of care, is the fact that IR has been shown to affect negatively
responses to IFN treatment, effectively lowering sustained
viral response (SVR) rates irrespective of genotype.115
A review by Negro lists a number of conflicting studies
regarding the impact of chronic HCV infection on cardiovas-
cular morbidity.116 It is not yet clear if the reported conditions
and observations, such as increased incidence of coronary
artery disease, stroke rate, and carotid plaque formation,
are a result of a systemic chronic inflammation, direct viral
action, or a consequence of IR.
The intricacies of the pathogenesis of IR, hepatic steatosis,
and metabolic syndrome are not yet fully understood, and the
fact that HCV is able to induce such changes and play a part in
suchacomplex interplayofmetabolicprocessesmeans it should
remain an important focus of research, even as new therapies
promise to make hepatitis C an easily managable condition.
Conclusions
Many epidemiological, clinical, and experimental studies have
shown that HCV infection is strongly associated with liver
steatosis, IR, and the development of T2DM. Our overview of
available clinical data further establishes this premise and,
with very few exceptions, shows the presence and strength of
this association across various groups of patients, providing a
strong foothold for future consideration of this topic. The
severity of hepatic steatosis in CHC arises from the combina-
tion of several host features (like visceral obesity, genetic
predisposition, medication use, and alcohol consumption) and
viral factors (including genotype, viral load, and gene muta-
tions), which interfere with lipid metabolism within the
hepatocytes or promote IR in the liver and peripheral tissues.
The presence and severity of HCV associated steatosis and
IR impact liver fibrosis severity and progression, lower rates
of response to interferon-based therapy, promote HCC devel-
opment, and probably increase cardiovascular morbidity.
The recognition of the link between HCV, steatosis, and MS
is important for improved patient treatment and care, and
many unresolved issues make it an intriguing area of future
research.
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